Biotech Stocks Are Surging in 2026. This One Stands Out After a Pullback.
With shares pulling back after a capital raise, this strategy offers double-digit upside potential in addition to downside protection of more than 20%.
Mag 7 Action Improves, But Biotech Keeps Delivering the Real Wins
While reverse rotation drives Nasdaq bounce, poor breadth suggests it can’t be trusted.
Going Back to the Well in a Sector That’s Working
After years of underperformance, biotech is finally catching a nice bid. Here’s my strategy on a name showing promise.
Stock Picking Is Working as Mag 7 and Chips Battle. Here’s What I’m Trading.
I’m heavily weighted in this one sector, while adding to one name on news.
The Rotation Out of AI Plays Out
The setup I have been describing for two weeks is now playing out. Here’s my best advice.
The Power of Market Rotation
There was a quick bounce in tech stocks, but I don’t trust it to last. Meanwhile, I’m building a July shopping list.
Palantir Breaks Support as Market Action Deteriorates Into the Close
Here’s why the setup is difficult as well as one area where the action is working.
This Biotech Could Become a ‘Sleeper’ Hit
Let’s look at this rising biopharma name working on several neurological condition treatments.